Wealthquest Corp Makes New $347,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Wealthquest Corp purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,923 shares of the company's stock, valued at approximately $347,000.

A number of other institutional investors have also recently bought and sold shares of KRYS. State of New Jersey Common Pension Fund D boosted its stake in Krystal Biotech by 19.3% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 11,803 shares of the company's stock worth $1,849,000 after buying an additional 1,910 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after buying an additional 3,727 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in Krystal Biotech by 11.9% during the fourth quarter. Illinois Municipal Retirement Fund now owns 14,146 shares of the company's stock worth $2,216,000 after buying an additional 1,505 shares in the last quarter. US Bancorp DE boosted its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Krystal Biotech by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock worth $38,095,000 after buying an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KRYS. Citigroup decreased their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, May 16th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Tuesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of "Buy" and an average target price of $211.13.

Krystal Biotech Trading Up 0.1%

NASDAQ KRYS traded up $0.08 on Thursday, hitting $142.58. 321,736 shares of the company were exchanged, compared to its average volume of 288,963. The company has a market cap of $4.12 billion, a P/E ratio of 34.27 and a beta of 0.65. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The firm has a 50 day moving average of $141.78 and a two-hundred day moving average of $158.46.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. Research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).